PDCD1 and cancer: Nivolumab is an immunotherapy medication approved for the treatment of metastatic or unresectable melanoma and as adjuvant therapy in patients with lymph node involvement, which blocks programmed cell death 1 ligand 1 (PD-L1) from binding to PD-1, allowing the immune response to cancer cell.